You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Acalabrutinib

Showing 26 - 50 of 137
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Acalabrutinib
  • Axicabtagene Ciloleucel
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Acalabrutinib
  • +8 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)

Active, not recruiting
  • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
  • Acalabrutinib capsule
  • Ahmedabad, India
  • +12 more
Feb 2, 2023

Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)

Not yet recruiting
  • Lymphoma
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Waldenstrom Macroglobulinemia Trial in Canada (Acalabrutinib, Bendamustine, Rituximab)

Recruiting
  • Waldenstrom Macroglobulinemia
  • Acalabrutinib
  • +2 more
  • Calgary, Alberta, Canada
  • +8 more
Nov 9, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • Obinutuzumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Lymphoma, Leukemia Trial (Acalabrutinib, tacrolimus, methotrexate)

Withdrawn
  • Lymphoma
  • Leukemia
  • Acalabrutinib, tacrolimus, methotrexate
  • (no location specified)
Feb 20, 2022

Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • Acalabrutinib
  • New York, New York
    Weill Cornell Medicine
Mar 25, 2022

CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
Mar 24, 2022

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
Has Results
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Acalabrutinib
  • +4 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Chronic Lymphocytic Leukemia Trial in Poland, United Kingdom (Ceralasertib, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Kraków, Poland
  • +10 more
Dec 2, 2022

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Acalabrutinib
  • +2 more
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • ACALABRUTINIB
  • +2 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Acalabrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 14, 2022

Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)

Recruiting
  • Food Allergy
  • Food Allergy Peanut
  • Acalabrutinib
  • Baltimore, Maryland
    Johns Hopkins Bayview Medical Center
Dec 30, 2021

Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in

Recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Acalabrutinib
  • Duarte, California
    City of Hope Medical Center
Mar 9, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)

Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • R-CHOP chemotherapy
  • Vancouver, British Columbia, Canada
  • +3 more
Mar 17, 2022

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Rochester (Acalabrutinib, Rituximab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
Feb 7, 2022

Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +9 more
Jul 13, 2022